elevenostat (JB3-22)
/ BioVision
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
November 21, 2021
Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma.
(PubMed, JCI Insight)
- "Elevenostat demonstrated nanomolar ex vivo activity in 34 MM patient specimens and synergistic activity when combined with bortezomib. Collectively, our data indicate that HDAC11 is an emerging therapeutic vulnerability in MM by targeting an essential pathway in PC biology."
Journal • Hematological Malignancies • Immunology • Multiple Myeloma • Oncology • HDAC11
1 to 1
Of
1
Go to page
1